Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Iida, Mari ^a   Brand, Toni M ^a   Starr, Megan M ^a   Huppert, Evan J ^a   Luthar, Neha ^a   Bahrar, Harsh ^a   Coan, John P ^a   Pearson, Hannah E ^a   Salgia, Ravi ^b   Wheeler, Deric L ^a  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acquired cetuximab resistance; AKT; Cetuximab; EGFR; HER3; MAPK; Non small cell lung cancer; U3 1287

Indexed keywords

CASPASE 3; CASPASE 7; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI 67; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; U 3 1287; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; MALE; MOLECULAR CLONING; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84928784872     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-242     Document Type: Article

References (56)

1. Wheeler DL, Dunn EF, Harari PM: Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 1, 7:493-507. 10.1038/nrclinonc.2010.97
2. Yarden Y, Pines G: The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 1, 12:553-563. 10.1038/nrc3309
3. Ang KK, Andratschke NH, Milas L: Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 1, 58:959-965. 10.1016/j.ijrobp.2003.07.010
4. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001,37(Suppl 4):S9-S15.
5. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, Benedetti-Panici P, Paludetti G, Scambia G, Mancuso S: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1, 74:1253-1257. 10.1038/bjc.1996.525
6. Lo HW: EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol 1, 3:37-52. 10.2174/1874467211003010037
7. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 1, 7:301-311. 10.1016/j.ccr.2005.03.003
8. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 1, 354:567-578. 10.1056/NEJMoa053422
9. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 1, 351:337-345. 10.1056/NEJMoa033025
10. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U, Flex Study Team: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 1, 373:1525-1531. 10.1016/S0140-6736(09)60569-9
11. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 1, 28:911-917. 10.1200/JCO.2009.21.9618
12. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 1, 23:1803-1810. 10.1200/JCO.2005.08.037
13. Arteaga CL: EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 1, 21:289s-291s. 10.1200/JCO.2003.10.523
14. Bianco R, Troiani T, Tortora G, Ciardiello F: Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer 2005,12(Suppl 1):S159-S171.
15. Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL: Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biol Ther 1, 12:436-446. 10.4161/cbt.12.5.16394
16. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL: Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 1, 28:3801-3813. 10.1038/onc.2009.234
17. Li C, Iida M, Dunn EF, Wheeler DL: Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiother Oncol 1, 97:330-337. 10.1016/j.radonc.2010.06.010
18. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM: Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 1, 27:3944-3956. 10.1038/onc.2008.19
19. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM: Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 1, 8:696-703. 10.4161/cbt.8.8.7903
20. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC: Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 1, 9:748-760. 10.2174/156800909789271495
21. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O: Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 1, 15:5445-5456. 10.1158/1078-0432.CCR-08-2980
22. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM: Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 1, 15:1585-1592. 10.1158/1078-0432.CCR-08-2068
23. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 1, 316:1039-1043. 10.1126/science.1141478
24. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 1, 445:437-441. 10.1038/nature05474
25. Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, Tindell C, Agus DB: HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res 1, 70:1989-1999. 10.1158/0008-5472.CAN-09-3326
26. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA: Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 1, 10:39-50. 10.1016/j.ccr.2006.05.024
27. Baselga J, Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 1, 9:463-475. 10.1038/nrc2656
28. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J: Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A 1, 106:21608-21613. 10.1073/pnas.0912101106
29. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA: ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A 1, 107:7692-7697. 10.1073/pnas.1002753107
30. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC: ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 1, 102:3788-3793. 10.1073/pnas.0409773102
31. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E: HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst 1, 105:266-273. 10.1093/jnci/djs501
32. Muller-Tidow C, Diederichs S, Bulk E, Pohle T, Steffen B, Schwable J, Plewka S, Thomas M, Metzger R, Schneider PM, Brandts CH, Berdel WE, Serve H: Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 1, 65:1778-1782. 10.1158/0008-5472.CAN-04-3388
33. Bae SY, La Choi Y, Kim S, Kim M, Kim J, Jung SP, Choi MY, Lee SK, Kil WH, Lee JE, Nam SJ: HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. Breast Cancer Res Treat 1, 139:741-750. 10.1007/s10549-013-2570-6
34. Beji A, Horst D, Engel J, Kirchner T, Ullrich A: Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res 1, 18:956-968. 10.1158/1078-0432.CCR-11-1186
35. Freeman DJ, Ogbagabriel S, Rothe M, Radinsky R, Treder M: Fully Human Anti-HER3 Monoclonal Antibodies (mAbs) Have Unique in Vitro and in Vivo Functional and Antitumor Activities Versus Other HER Family Inhibitors [abstract]. In AACR Meeting. San Diego, CA; 2008:LB-21.
36. Treder M, Ogbafabriel S, Moor R, Schulze-Horsel U, Hettmann T, Rothe M, Radinsky M, Freeman D: Fully human anti-HER3 mAb U3-1287 (AMG888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models [abstract]. Eur J Cancer 2008,6(suppl):309.
37. Freeman DJ, Ogbagabriel S, Bready J, Sun J-K, Radisnky R, Hettmann T: U3-1287 (AMG888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo eddicacy in the FaDu moel of human squamous cell carcinoma of the head and neck (SCCHN). Mol Cancer Ther 2011,10(Suppl 1):abstract A182.
38. Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL: Sym004, a novel EGFR antibody mixture, Can overcome acquired resistance to cetuximab. Neoplasia 2013, 15:1196-1206.
39. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL: Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 1, 108:5021-5026. 10.1073/pnas.1016140108
40. Gala K, Chandarlapaty S: Molecular pathways: HER3 targeted therapy. Clin Cancer Res 1, 20:1410-1416. 10.1158/1078-0432.CCR-13-1549
41. Zhang L, Castanaro C, Luan B, Yang K, Fan L, Fairhurst JL, Rafique A, Potocky TB, Shan J, Delfino FJ, Shi E, Huang T, Martin JH, Chen G, Macdonald D, Rudge JS, Thurston G, Daly C: ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther 1, 13:1345-1355. 10.1158/1535-7163.MCT-13-1033
42. Quesnelle KM, Grandis JR: Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 1, 17:5935-5944. 10.1158/1078-0432.CCR-11-0370
43. Zheng L, Tan W, Zhang J, Yuan D, Yang J, Liu H: Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling. Cancer Immunol Immunother 1, 63:581-586. 10.1007/s00262-014-1541-z
44. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B: HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One 1, 3:e2881. 10.1371/journal.pone.0002881
45. Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA 3rd, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX: Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 1, 20:456-468. 10.1158/1078-0432.CCR-13-0358
46. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 1, 487:505-509. 10.1038/nature11249
47. Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M: Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal 1, 7:ra29. 10.1126/scisignal.2005125
48. Sarup J, Jin P, Turin L, Bai X, Beryt M, Brdlik C, Higaki JN, Jorgensen B, Lau FW, Lindley P, Liu J, Ni I, Rozzelle J, Kumari R, Watson SA, Zhang J, Shepard HM: Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. Mol Cancer Ther 1, 7:3223-3236. 10.1158/1535-7163.MCT-07-2151
49. Hegde GV, de la Cruz CC, Chiu C, Alag N, Schaefer G, Crocker L, Ross S, Goldenberg D, Merchant M, Tien J, Shao L, Roth L, Tsai SP, Stawicki S, Jin Z, Wyatt SK, Carano RA, Zheng Y, Sweet-Cordero EA, Wu Y, Jackson EL: Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med 2013, 5:171ra118.
50. Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM: Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 1, 73:824-833. 10.1158/0008-5472.CAN-12-1611
51. el Bahassi M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ, Rixe O: A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer. Eur J Cancer 1, 49:2345-2355. 10.1016/j.ejca.2013.03.005
52. Johan L, Pedersen MW, Jacobsen HJ, Poulsen TT, Kjær I, Koefoed K, Sen JW, Weilguny D, Bjerregaard B, Andersen CR, Horak ID, Kragh M: Simultaneous inhibition of EGFR, HER2 and HER3 by an antibody mixture provides broad and potent tumor inhibition [abstract]. AACR Meeting 2013, 4751.
53. Li C, Brand TM, Iida M, Huang S, Armstrong EA, van der Kogel A, Wheeler DL: Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discov Med 2013, 16:79-92.
54. Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL: Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res 1, 19:610-619. 10.1158/1078-0432.CCR-12-2024
55. Wakui H, Yamamoto N, Nakamichi S, Tamura Y, Nokihara H, Yamada Y, Tamura T: Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER1, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2014, 73:511-516. 10.1007/s00280-014-2375-2
56. LoRusso P, Janne PA, Oliveira M, Rizvi N, Malburg L, Keedy V, Yee L, Copigneaux C, Hettmann T, Wu CY, Ang A, Halim AB, Beckman RA, Beaupre D, Berlin J: Phase I study of U3-1, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2013, 19:3078-3087. 10.1158/1078-0432.CCR-12-3051